

SACT Endometrial Cancer Treatments

Reference Number: RDF1537-23

Date of Response: 16/06/23

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1st April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

Dear Royal Devon University Healthcare NHS Foundation Trust,

I'm hoping that you will be able to help me with Freedom of Information request that I have, please see the below

- 1. Does your Trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments?*

Answer: Yes.

- 2. How many patients were treated for endometrial cancer in the past 6 months with the following treatments:*

Answer: Please see table below; date range 01 September 2022 to 28 February 2023, based on the latest available data.

In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients/staff and breach Caldicott principles. In these cases ≤ 5 is used to indicate that a figure between 1 and 5 is being suppressed.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.

<i>Drug Name</i>	<i>Total</i>
<i>Dostarlimab</i>	Nil
<i>Hormone therapy (Progesterone or Letrozole)</i>	≤ 5
<i>Pembrolizumab monotherapy</i>	Nil
<i>Pembrolizumab in combination with Lenvatinib</i>	Nil

<i>Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)</i>	15
<i>Any other SACT</i>	≤5

3. *How many endometrial cancer patients received the following therapies as 1st Line treatment in the past 6 months:*

Answer: Please see table below; date range 01 September 2022 to 28 February 2023, based on the latest available data.

<i>Drug Name</i>	<i>Total</i>
<i>Hormone therapy (Progesterone or Letrozole)</i>	≤5
<i>Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)</i>	6
<i>Any other SACT</i>	Nil

4. *Of the patients treated for endometrial cancer in the past 6 months with any SACT regimen, how many patients had high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR)?*

Answer: <5 patients.

5. *Does your Trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.*

Answer: Yes. AtTEnd - Atezolizumab in Endometrial cancer, <5 patients.